Compare LBRT & MIRM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | LBRT | MIRM |
|---|---|---|
| Founded | 2011 | 2018 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Oilfield Services/Equipment | Biotechnology: Pharmaceutical Preparations |
| Sector | Energy | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 4.1B | 4.2B |
| IPO Year | 2018 | 2019 |
| Metric | LBRT | MIRM |
|---|---|---|
| Price | $24.49 | $100.78 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 12 | 11 |
| Target Price | $22.08 | ★ $102.64 |
| AVG Volume (30 Days) | ★ 5.2M | 733.0K |
| Earning Date | 01-28-2026 | 02-26-2026 |
| Dividend Yield | ★ 1.47% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 0.89 | N/A |
| Revenue | ★ $4,006,116,000.00 | $471,794,000.00 |
| Revenue This Year | N/A | $55.91 |
| Revenue Next Year | $9.99 | $23.97 |
| P/E Ratio | $27.48 | ★ N/A |
| Revenue Growth | N/A | ★ 53.66 |
| 52 Week Low | $9.50 | $36.88 |
| 52 Week High | $27.21 | $105.74 |
| Indicator | LBRT | MIRM |
|---|---|---|
| Relative Strength Index (RSI) | 60.59 | 64.68 |
| Support Level | $24.13 | $97.49 |
| Resistance Level | $25.91 | $105.74 |
| Average True Range (ATR) | 1.63 | 3.71 |
| MACD | 0.00 | -0.79 |
| Stochastic Oscillator | 58.94 | 62.01 |
Liberty Energy Inc is a integrated energy services and technology company focused on providing hydraulic fracturing services and related technologies to onshore oil and natural gas exploration and production (E&P) companies. The Company offers customers with hydraulic fracturing services, together with complementary services including wireline services, proppant delivery solutions, field gas processing and treating, compressed natural gas (CNG) delivery, data analytics, related goods (including sand mine operations), and technologies to facilitate lower emission completions, thereby helping customers reduce emissions profile. The company provides services across USA and Canada.
Mirum Pharmaceuticals Inc is a biopharmaceutical company focused on the identification, acquisition, development, and commercialization of novel therapies for debilitating rare and orphan diseases. Its product, Livmarli, a novel, orally administered, minimally-absorbed ileal bile acid transporter IBAT) inhibitor (IBATi), is approved for the treatment of cholestatic pruritus in patients with Alagille syndrome (ALGS). It is involved in the development of Maralixibat for the treatment of pediatric patients with progressive familial intrahepatic cholestasis, or PFIC, and Alagille syndrome, or ALGS. The company is also involved in the development of volixibat for the treatment of adult patients with cholestatic liver diseases.